Brammer Bio
Brammer Bio is a viral vector CDMO providing end-to-end gene and cell therapy manufacturing services across AAV, lentiviral, and other vector types, now operating within Thermo Fisher Scientific's Patheon pharmaceutical services division under the Viral Vector Services brand.
- Company typePrivate
- Founded2015
- HeadquartersLexington, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingServices
What Brammer Bio does
Brammer Bio is a viral vector contract development and manufacturing organization (CDMO) specializing in gene therapy and cell therapy manufacturing, acquired by Thermo Fisher Scientific in 2019 for $1.7 billion and now operating as part of Thermo Fisher's Patheon pharmaceutical services division under the Viral Vector Services (VVS) brand. The company provides end-to-end services spanning process development, analytical development, clinical and commercial manufacturing, fill-finish, regulatory support, and cold chain logistics for biotechnology and pharmaceutical customers developing gene therapies and gene-modified cell therapies. Its customer base includes gene therapy developers (such as bluebird bio and NysnoBio) and cell therapy companies requiring lentiviral vectors for CAR-T applications.
The core technology platform supports multiple viral vector types including adeno-associated virus (AAV), lentiviral (LV), adenoviral, retroviral, herpesviral, MVA, VSV, and virus-like particles across both suspension (up to 2,000L) and adherent cell culture platforms. Proprietary capabilities include the Rapid Development Framework™ (9-month GMP delivery timeline), triple transfection and infection techniques for AAV across serotypes, stable packaging cell line-based processes for lentiviral vectors, chromatography-based purification with full capsid separation, and semi/fully automated fill-finish lines. The infrastructure spans over 555,000 square feet across four sites: Plainville, MA (290,000 ft² for end-to-end viral vector services), Cambridge, MA (140,000 ft² for late-phase and commercial manufacturing since 2018, with first commercial license in Q1 2021), Seneffe, Belgium (34,000 ft² with EMA approval history), and Gosselies, Belgium (8,300 ft² for process development and analytical work).
Revenue is generated through long-term contract fees for clinical and commercial CDMO services, with quote-based pricing driven by project-specific requirements, scale, and contract terms. The go-to-market model is enterprise direct sales with dedicated account teams, technical sales representatives, and regulatory affairs specialists engaging biotech and pharmaceutical customers. The company has manufactured 1,100+ viral vector lots cumulatively, holds 3 commercially approved products, and is conducting 8 upcoming/ongoing Process Performance Qualification (PPQ) batches.
Brammer Bio firmographics
Firmographics- Name
- Brammer Bio
- Legal name
- Brammer Bio
- Website
- https://brammerbio.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Acquired
- Headcount range
- 501–1,000 employees
- Short description
- Brammer Bio is a viral vector CDMO providing end-to-end gene and cell therapy manufacturing services across AAV, lentiviral, and other vector types, now operating within Thermo Fisher Scientific's Patheon pharmaceutical services division under the Viral Vector Services brand.
- Ownership category
- akta.pro rank
Brammer Bio industry classification
Industry- Product category
- Viral Vector Contract Development and Manufacturing (CDMO)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Gene Therapy CDMO (Viral Vector Manufacturing) (HLAGAGAB)
- akta.pro secondary industries
- Gene Therapy (Viral Vector/Plasmid) CDMO (HLAGABAE), Viral Vector Manufacturing Services (AAV, lentiviral, adenoviral) (HLAAAKAD), Gene Therapy Vector Manufacturing & CDMO Services (HLAAACAJ), Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN)
Keywords
Where Brammer Bio is headquartered
LocationHeadquarters
- HQ city
- Lexington
- HQ country
- United States
- HQ region
- North America
Offices4 records
Markets served
Brammer Bio business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain, Marketing or Sales
Revenue model
- Viral Vector CDMO Services: Contract development and manufacturing organization providing end-to-end services for viral vector development and commercialization. Revenue generated through long-term manufacturing contracts for clinical trial material and commercial product supply. Services span process development, analytical development, clinical manufacturing, commercial manufacturing, and fill-finish services. Customers include biotech and pharmaceutical companies developing gene therapies and gene-modified cell therapies.
- M&A Acquisition Value: Brammer Bio was acquired by ThermoFisher Scientific for $1.7 billion as part of their strategy to expand cell and gene therapy CDMO capabilities. The company now operates as part of Thermo Fisher's Viral Vector Services (VVS) division under the Patheon brand.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Brammer Bio product offering
Product offeringCore offering
Brammer Bio is a contract development and manufacturing organization (CDMO) that develops and produces viral vectors—primarily adeno-associated virus (AAV) and lentiviral vectors—for gene therapy and gene-modified cell therapy programs. The company delivers end-to-end services including upstream and downstream process development, analytical development, CGMP clinical and commercial manufacturing on adherent and suspension platforms up to 2,000L, aseptic fill-finish, and global regulatory support.
Product overview
Brammer Bio, acquired by Thermo Fisher Scientific in 2019 for $1.7 billion, is a viral vector CDMO specializing in gene therapy manufacturing. The company's offerings are now integrated into Patheon Pharma Services as part of Thermo Fisher Scientific's Advanced Therapies division. The portfolio includes Viral Vector Manufacturing Services (VVS) as the core offering, with sub-products covering Adeno-Associated Virus (AAV) vectors and Lentiviral vectors (LV), plus supporting modules including Rapid Development Framework™ for accelerated 9-month GMP delivery, Process Development Services, Regulatory Services, and Cold Chain Logistics. The services span from early development through commercial manufacturing, with facilities in the US (Plainville, MA; Cambridge, MA) and Europe (Seneffe, Belgium; Gosselies, Belgium), leveraging expertise from Brammer Bio, Henogen S.A., and Fisher Clinical Services.
Differentiator
Problem solved
Functional benefit
Products and services
- Viral Vector Manufacturing Services (VVS) End-to-end contract development and manufacturing services for viral vectors used in gene therapies and gene-modified cell therapies, covering process and analytical development, CGMP clinical and commercial manufacturing, aseptic fill-finish, and global regulatory support for biotech and pharmaceutical customers.
- Adeno-Associated Virus (AAV) Vector Manufacturing Process development and CGMP manufacturing of adeno-associated virus vectors across multiple serotypes using triple transfection and infection techniques on adherent and suspension platforms, for pre-clinical, clinical, and commercial gene therapy applications.
- Lentiviral Vector (LV) Manufacturing Process development and CGMP manufacturing of lentiviral vectors using both transient transfection and stable packaging cell line-based processes on adherent and suspension platforms, supporting CAR-T and other gene-modified cell therapies.
Quantifiable outcome
- GMP drug product delivery in as little as 9 months using Rapid Development Framework
- +3 more outcomes
Companies that use Brammer Bio
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles1 record
Brammer Bio technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Brammer Bio partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core.
- ThermoFisher ScientificcoreThermoFisher Scientific acquired Brammer Bio for $1.7 billion in 2019 as a strategic acquisition to expand its cell and gene therapy CDMO capabilities. Brammer Bio's viral vector manufacturing expertise was integrated into Thermo Fisher's Patheon division to create a leading viral vector services offering. The company now operates as part of Thermo Fisher's Viral Vector Services (VVS) division.
- Henogen S.A.coreViral vector knowledge and experience from Henogen S.A. has been leveraged within Thermo Fisher's Viral Vector Services. Henogen contributed expertise in virus and viral vector manufacturing that enhances the combined organization's capabilities across multiple viral vector types.
- Fisher Clinical ServicescoreClinical trial capabilities from Fisher Clinical Services have been integrated into the Viral Vector Services offering, providing global clinical supply chain, cold chain logistics, and distribution capabilities to support customers throughout clinical development.
Scale indicators10 records
Recent moves6 records
Expansion highlights6 records
Brammer Bio competitors and assessment
Company assessmentDirect peers
- Lonza Cell & Gene Technologies: One of the largest CDMOs globally with significant viral vector manufacturing capacity for gene therapies. Directly competes with Brammer Bio in AAV and lentiviral vector CDMO services across US and European markets.
- Vibalogics: Specialized CDMO focused on virus and viral vector manufacturing (oncolytic, vaccine, gene therapy). Directly competes with Brammer Bio in viral vector CDMO services, particularly for niche and complex programs.
- Yposkesi: European viral vector CDMO specializing in AAV and lentiviral vector manufacturing for gene therapy. Comparable to Brammer Bio in viral vector services though operating primarily in the European market with smaller scale.
- AGC Biologics: CDMO offering viral vector and cell therapy manufacturing services. Competes with Brammer Bio in AAV and lentiviral vector manufacturing for gene therapy clinical and commercial programs.
- Charles River Laboratories: CDMO with viral vector manufacturing capabilities following acquisitions of Cognate BioServices and Vigene Biosciences. Competes directly with Brammer Bio in viral vector CDMO services for gene and cell therapy developers.
- WuXi AppTec: Global CDMO offering cell and gene therapy manufacturing services including viral vector production. Direct competitor with comparable service offerings across process development, manufacturing, and fill-finish.
- Catalent: Global CDMO with leading cell and gene therapy manufacturing capabilities, including viral vector production. Direct competitor to Brammer Bio's AAV and lentiviral vector CDMO services across clinical and commercial stages.
Broad incumbents
- Samsung Biologics: Large-scale biologics CDMO expanding into cell and gene therapy services. While broader in scope, Samsung represents an emerging threat in viral vector manufacturing as it invests in gene therapy CDMO capabilities.
- Patheon Pharma Services (Thermo Fisher): Broader pharmaceutical services division of Thermo Fisher, now housing Brammer Bio. While Brammer Bio is part of Patheon, the wider division provides context on its integration into Thermo Fisher's broader CDMO portfolio.
Emerging players
- Eurofins CDMO: Global CDMO offering biologics and advanced therapy manufacturing services including viral vectors. Comparable peer in the viral vector CDMO space though with more diversified service offerings beyond gene therapy.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Brammer Bio social profiles
Digital presenceBrammer Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Brammer Bio leadership team
Management profileNumber of profiles
Profiles1 record
Brammer Bio funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Brammer Bio M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Brammer Bio
What does Brammer Bio do?
Brammer Bio is a contract development and manufacturing organization (CDMO) that develops and produces viral vectors—primarily adeno-associated virus (AAV) and lentiviral vectors—for gene therapy and gene-modified cell therapy programs. The company delivers end-to-end services including upstream and downstream process development, analytical development, CGMP clinical and commercial manufacturing on adherent and suspension platforms up to 2,000L, aseptic fill-finish, and global regulatory support.
Is Brammer Bio a public or private company?
Brammer Bio is a private company. It is classified as corporate owned and is currently acquired.
When was Brammer Bio founded?
Brammer Bio was founded in 2015. It employs 501 to 1,000 people.
Where is Brammer Bio based?
Brammer Bio is headquartered in Lexington, United States, in the North America region.
How does Brammer Bio make money?
Two revenue lines are on record. Viral Vector CDMO Services are the primary driver. The others are M&A Acquisition Value.
Who are Brammer Bio's main competitors?
Direct peers on record are Lonza Cell & Gene Technologies, Vibalogics, Yposkesi, AGC Biologics, Charles River Laboratories, WuXi AppTec and Catalent. Broad incumbents are Samsung Biologics and Patheon Pharma Services (Thermo Fisher). Eurofins CDMO is listed as an emerging player.
Does Brammer Bio have an API?
No public API is recorded for Brammer Bio.
What industry is Brammer Bio in?
Brammer Bio's product category is Viral Vector Contract Development and Manufacturing (CDMO). Its primary akta.pro industry code is HLAGAGAB, Gene Therapy CDMO (Viral Vector Manufacturing), with a secondary code of HLAGABAE, Gene Therapy (Viral Vector/Plasmid) CDMO. Its NAICS code is 541714 and its SIC code is 8731.